FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

07/17/14 - 20140199313 - Process for the production of fine chemicals
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host...

07/17/14 - 20140199314 - Methods and compositions for regulating iron homeostasis by modulation of bmp-6
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation....

07/17/14 - 20140199315 - Sp35 antibodies and uses thereof
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of...

07/17/14 - 20140199316 - Methods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO...

07/17/14 - 20140199317 - Actriia binding agents and uses thereof
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same....

07/17/14 - 20140199318 - Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia....

07/10/14 - 20140193417 - Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to...

07/10/14 - 20140193418 - Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD....

07/10/14 - 20140193419 - Methods and compositions for treating and diagnosing diseases
Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in...

07/10/14 - 20140193420 - Diagnosis and treatment of cancer using anti-itm2a antibody
Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a...

07/10/14 - 20140193421 - Anti-human xcr1 antibodies
An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and...

07/03/14 - 20140186357 - Method for treatment of degenerative brain disorders comprising inhibitor of sum01 and bace1 interaction as an active ingredient
A treatment method for degenerative brain disorders using a pharmaceutically effective dose of the inhibitor of SUMO1 (small ubiquitin-like modifier 1) and BACE1 (β-secretase) interaction, or the inhibitor of SUMO1 expression or activation is provided. More specifically, it was confirmed that SUMO1 increased BACE1 accumulation and Aβ generation, that is...

07/03/14 - 20140186358 - Her3 antibodies binding to the beta-hairpin of her3
The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament....

07/03/14 - 20140186359 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide...

06/26/14 - 20140178390 - Biological materials related to cxcr7
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present...

06/26/14 - 20140178391 - Colon disease targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as...

06/26/14 - 20140178392 - Nogo receptor-mediated blockade of axonal growth
Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in...

06/26/14 - 20140178393 - Amino acid sequence presenting fusion polypeptide and its use
Herein is reported a fusion polypeptide according to formula (I): NH2—S2—X1—S1—COOH, wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and denotes a peptide bond, wherein the...

06/26/14 - 20140178394 - Novel antigen peptide and uses thereof
The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer....

06/26/14 - 20140178395 - Treatment of nephropathy
The present invention relates to treatment of nephropathy. In particular, the present invention relates to treatment of nephropathy using therapeutic antibodies....

06/26/14 - 20140178396 - Treatment of cardiovascular diseases
The present invention relates to treatment of cardiovascular diseases and arthero-sclerosis. In particular, the present invention relates to use of therapeutic antibodies....

06/26/14 - 20140178397 - Anti-angiogenic therapy
The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis....

06/19/14 - 20140170152 - Immunobinders directed against tnf
Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies....

06/19/14 - 20140170153 - Il-21 epitope and il-21 ligands
The present invention relates to IL-21 ligands, such as e.g. antibodies, as well as use thereof....

06/19/14 - 20140170154 - Engineered anti-il-23r antibodies
Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders....

06/19/14 - 20140170155 - Method for treating a gd2 positive cancer
Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more...

06/12/14 - 20140161807 - Methods of promoting cns neuronal repair by inhibiting lrp-1
This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1)....

06/12/14 - 20140161808 - Antibodies that bind novel pcsk9 variants
The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the...

06/12/14 - 20140161809 - Diagnostic and therapeutic target
An in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said...

06/05/14 - 20140154258 - Pharmaceutical compositions containing antibodies to neuropeptide head activator and methods thereof
This invention relates to pharmaceutical compositions comprising antibodies that specifically bind to the endogenous neuropeptide head activator (NHA) having the sequence of pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe and neutralize the function of NHA thereby. The invention also provides methods for neutralizing NHA function, and particularly for treating NHA-related disorders (e.g., cancer or cardiovascular diseases)...

06/05/14 - 20140154259 - Method for the treatment of inflammatory disorders
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1....

06/05/14 - 20140154260 - B-7 related nucleic acids and polypeptides useful for immunomodulation
The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated...

06/05/14 - 20140154261 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides...

05/29/14 - 20140147444 - Selective binding agents of osteoprotegerin binding protein
Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies...

05/29/14 - 20140147445 - Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed....

05/22/14 - 20140141001 - Anit-human interleukin-20 antibodies
Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods...

05/22/14 - 20140141002 - Method for inhibiting cellular activation by insulin-like growth factor-1
A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit...

05/22/14 - 20140141003 - Neutralizing prolactin receptor antibody mat3 and its therapeutic use
The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids,...

05/22/14 - 20140141004 - Immunogenic peptides and methods of use for treating and preventing cancer
Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor...

05/15/14 - 20140134173 - Composition and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
Methods of using binding molecules and fragments thereof that bind to the protein target Dickkopf-1 (DKK1), Dickkopf-4 (DKK4) or both (wherein specificity to DKK1 or DKK4 or both is herein denoted as “DKK1/4”) are provided....

05/15/14 - 20140134174 - Soga polynucleotides and polypeptides and uses thereof
The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the...

05/15/14 - 20140134175 - Human antibodies against hepatitis c virus (hcv) and uses thereof
Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J...

05/15/14 - 20140134176 - Platelet-derived growth factor b specific antibodies and compositions and uses thereof
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of...

05/15/14 - 20140134177 - Compositions and methods for treating and diagnosing cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin...

05/15/14 - 20140134178 - Phosphorylation of histones and uses thereof
Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific...

05/08/14 - 20140127212 - Binding members for ige molecules
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma....

05/08/14 - 20140127213 - Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof
The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and...

05/08/14 - 20140127214 - Natural igm antibodies and inhibitors thereof
The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders....

05/08/14 - 20140127215 - Clostridium difficile antigens
Compositions and methods for the treatment or prevention of Clostridium difficile infection in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate or prevent relapse of Clostridium difficile bacterial infection and/or induce an immune response to...

05/08/14 - 20140127216 - Novel expression cassette for efficient surface display of antigenic proteins
An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane...

05/08/14 - 20140127217 - Pharmaceutical compositions and methods to vaccinate against candidiasis
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the...

05/08/14 - 20140127218 - Pharmaceutical compositions and methods to vaccinate against candidiasis
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the...

05/08/14 - 20140127219 - Antibodies for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the...

05/08/14 - 20140127220 - Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals....

05/08/14 - 20140127221 - Genes of an otitis media isolate of nontypeable haemophilus influenzae
The invention relates to the polynucleotide sequence of a nontypeable strain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx....